◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksW › WGS

GeneDx Holdings Corp. (WGS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-09-03

GeneDx Holdings Corp. (WGS) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Stamford, United States with about 1,300 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, WGS reported $428M in revenue and ($21M) in net income.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.

Interactive charts & full statements → Open the WGS valuation workbench →

WGS Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Total Revenue$454M$428M$305M$203M$235M$212M$179M$196M
Gross Profit$310M$298M$194M$90M($27M)($17M)$4M$83M
Gross Margin %68.2%69.7%63.6%44.4%-11.4%-7.8%2.2%42.2%
Operating Income (EBIT)($61M)($12M)($23M)($181M)($668M)($446M)($242M)($30M)
Operating Margin %-13.3%-2.8%-7.6%-89.1%-284.5%-210.2%-134.9%-15.5%
Net Income($106M)($21M)($52M)($176M)($549M)($245M)($241M)($30M)
Net Margin %-23.4%-4.9%-17.1%-86.8%-233.9%-115.6%-134.6%-15.1%
EBITDA($76M)$7M($28M)($136M)($398M)($221M)($227M)($23M)
Earnings Per Share (EPS)$-3.68$-0.78$-1.94$-7.23$-53.63$-74.93$-42.89$-5.28
Shares Outstanding (M)30M27M27M24M10M3M6M6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WGS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$114M$102M$121M$117M$103M$87M$96M$77M
Gross Profit$78M$68M$79M$85M$71M$58M$66M$48M
Gross Margin %68.4%66.7%65.2%72.4%69.0%67.1%69.2%62.2%
Operating Income (EBIT)($17M)($26M)($14M)($3M)$9M($5M)$9M($8M)
Operating Margin %-15.2%-25.6%-11.3%-2.8%8.7%-5.2%9.2%-10.1%
Net Income($18M)($63M)($18M)($8M)$11M($7M)$5M($8M)
Net Margin %-15.5%-61.9%-14.6%-6.5%10.5%-7.5%5.7%-10.8%
EBITDA($10M)($55M)($11M)$0M$18M$0M$12M($2M)
Earnings Per Share (EPS)$-0.60$-2.16$-0.66$-0.27$0.36$-0.23$0.20$-0.31
Shares Outstanding (M)30M29M27M29M30M28M27M27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WGS Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash from Operations (CFO)($49M)$33M($28M)($180M)($319M)($190M)($93M)($19M)
Capital Expenditures (CapEx)$27M$19M$5M$6M$14M$21M$32M$15M
Free Cash Flow (FCF)($76M)$14M($34M)($186M)($333M)($211M)($125M)($34M)
FCF Margin %-16.7%3.3%-11.1%-91.8%-142.1%-99.5%-69.8%-17.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WGS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($29M)($32M)($3M)$16M$10M$10M($3M)($4M)
Capital Expenditures (CapEx)$10M$6M$4M$6M$2M$6M$3M$1M
Free Cash Flow (FCF)($39M)($39M)($7M)$10M$8M$4M($6M)($5M)
FCF Margin %-34.2%-38.0%-6.2%8.2%7.8%4.7%-6.5%-6.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WGS Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Total Assets$481M$570M$419M$419M$545M$554M$252M
Cash & Cash Equivalents$60M$105M$85M$100M$137M$401M$108M
Total Liabilities$237M$262M$174M$191M$292M$166M$247M
Total Debt (Short + Long-Term)$103M$57M$55M$57M$17M$14M$22M$0M
Total Shareholders' Equity$244M$308M$245M$228M$254M$388M$4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive WGS viewer.

Other Companies in DIAGNOSTICS & RESEARCH

← WGRXAll “W” companiesWGX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.